Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 8
1976 26
1977 14
1978 30
1979 43
1980 43
1981 62
1982 86
1983 71
1984 64
1985 73
1986 80
1987 77
1988 88
1989 70
1990 74
1991 48
1992 43
1993 54
1994 61
1995 51
1996 39
1997 39
1998 35
1999 48
2000 39
2001 38
2002 41
2003 41
2004 34
2005 53
2006 50
2007 61
2008 40
2009 31
2010 23
2011 32
2012 28
2013 36
2014 34
2015 32
2016 31
2017 20
2018 21
2019 22
2020 11
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,978 results
Results by year
Filters applied: . Clear all
Page 1
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.
POISE Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Málaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. POISE Study Group, et al. Lancet. 2008 May 31;371(9627):1839-47. doi: 10.1016/S0140-6736(08)60601-7. Epub 2008 May 12. Lancet. 2008. PMID: 18479744 Free article. Clinical Trial.
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0053). ...Patients are unlikely to accept the risks associated with perioperative extended-release metoprolol....
More patients in the metoprolol group than in the placebo group had a stroke (41 [1.0%] vs 19 [0.5%] patients; 2.17, 1.26-3.74; p=0.0 …
Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.
Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Hjalmarson A, et al. JAMA. 2000 Mar 8;283(10):1295-302. doi: 10.1001/jama.283.10.1295. JAMA. 2000. PMID: 10714728 Clinical Trial.
OBJECTIVE: To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality, hospitalization, symptoms, and quality of life in patients with heart failure. ...NYHA functional class, assessed by phys …
OBJECTIVE: To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR …
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Chen ZM, et al. Lancet. 2005 Nov 5;366(9497):1622-32. doi: 10.1016/S0140-6736(05)67661-1. Lancet. 2005. PMID: 16271643 Clinical Trial.
FINDINGS: Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For death, reinfarction, or cardiac arrest, 2166 (9.4%) patients allocated metoprolol had at least one such event compared with 2261 (9.9%) allocated placebo (odds ra …
FINDINGS: Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For death, reinfarction, or cardi …
Comparison of bisoprolol to a metoprolol CR/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study.
Yang T, Jiang Y, Hao Y, Zhou S, Xu X, Qu B, Lin X, Ma T. Yang T, et al. Hypertens Res. 2017 Jan;40(1):79-86. doi: 10.1038/hr.2016.101. Epub 2016 Aug 18. Hypertens Res. 2017. PMID: 27534738 Clinical Trial.
This open-label study investigated the long action of bisoprolol compared with metoprolol CR/ZOK for controlling the mean dynamic heart rate (HR) and blood pressure (BP) in patients with mild-to-moderate primary hypertension. ...Noncompliance was reported in 3 (3.53%) and …
This open-label study investigated the long action of bisoprolol compared with metoprolol CR/ZOK for controlling the mean dynamic hea …
Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group.
[No authors listed] [No authors listed] Am J Cardiol. 1985 Nov 22;56(14):39G-46G. Am J Cardiol. 1985. PMID: 3904393 Clinical Trial.
Left ventricular failure was observed no more often in the metoprolol group. The occurrence of cardiogenic shock also did not differ between the groups. ...Atropine (4.1 vs 6.4%) and sympathomimetic (3.2 vs 4.6%) agents were used more often in the metoprolol group d …
Left ventricular failure was observed no more often in the metoprolol group. The occurrence of cardiogenic shock also did not differ …
Cost-effectiveness of nitrendipine and hydrochlorothiazide or metoprolol to treat hypertension in rural community health centers in China.
Wang Z, Chen Z, Wang X, Hao G, Ma L, Zhao X, Li Y, Zhang L, Zhu M. Wang Z, et al. J Hypertens. 2017 Apr;35(4):886-892. doi: 10.1097/HJH.0000000000001209. J Hypertens. 2017. PMID: 27977472 Free PMC article. Clinical Trial.
OBJECTIVES: The objective of this article is to compare blood pressure (BP)-lowing effects of nitrendipine and hydrochlorothiazide and nitrendipine and metoprolol, and estimate the economic effect of these therapies on hypertension. ...Comparing with nitrendipine and me
OBJECTIVES: The objective of this article is to compare blood pressure (BP)-lowing effects of nitrendipine and hydrochlorothiazide and nitre …
Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience.
Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, Portman RJ, Falkner B; Toprol-XL Pediatric Hypertension Investigators. Batisky DL, et al. J Pediatr. 2007 Feb;150(2):134-9, 139.e1. doi: 10.1016/j.jpeds.2006.09.034. J Pediatr. 2007. PMID: 17236889 Clinical Trial.
OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate (ER metoprolol) in children 6 to 16 years of age with established hypertension. STUDY DESIGN: Patients were randomized to one of four …
OBJECTIVE: To evaluate the efficacy, tolerability, and blood pressure (BP) lowering effect of extended release metoprolol succinate ( …
MERIT-HF--description of the trial.
Wikstrand J. Wikstrand J. Basic Res Cardiol. 2000;95 Suppl 1:I90-7. doi: 10.1007/s003950070016. Basic Res Cardiol. 2000. PMID: 11192361 Review.
It was recommended to double the dose after each 2-week period in order to reach the highest tolerated dose aiming for a target dose level of 200 mg once daily of metoprolol CR/Zok or placebo. This dosage regimen could be modified according to the judgement of the investig …
It was recommended to double the dose after each 2-week period in order to reach the highest tolerated dose aiming for a target dose level o …
Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. Goryachkina K, et al. Eur J Clin Pharmacol. 2008 Mar;64(3):275-82. doi: 10.1007/s00228-007-0404-3. Epub 2007 Nov 29. Eur J Clin Pharmacol. 2008. PMID: 18043911 Clinical Trial.
Patients were genotyped for CYP2D6 3, 4 and gene duplication. Metoprolol and alpha-hydroxy-metoprolol were analyzed in plasma 0, 2, 6 and 12 h post-dose. ...We suggest, however, that the metoprolol dose is controlled upon initiation and withdrawal of paroxeti …
Patients were genotyped for CYP2D6 3, 4 and gene duplication. Metoprolol and alpha-hydroxy-metoprolol were analyzed in plasma …
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).
Wikstrand J, Hjalmarson A, Waagstein F, Fagerberg B, Goldstein S, Kjekshus J, Wedel H; MERIT-HF Study Group. Wikstrand J, et al. J Am Coll Cardiol. 2002 Aug 7;40(3):491-8. doi: 10.1016/s0735-1097(02)01970-8. J Am Coll Cardiol. 2002. PMID: 12142116 Free article. Clinical Trial.
OBJECTIVES: We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) with the aim of reporting on the heart rate (HR) response during the titration phase and clinical outcomes from the three-month f …
OBJECTIVES: We performed a post-hoc subgroup analysis in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure …
1,978 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page